Pet Vivo Holdings, Inc. PETV
We take great care to ensure that the data presented and summarized in this overview for PetVivo Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PETV
Top Purchases
Top Sells
About PETV
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at PETV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 16
2024
|
Robert James Rudelius Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+15.82%
|
-
|
|
Oct 16
2024
|
John Spencer Breithaupt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+50.0%
|
-
|
|
Oct 16
2024
|
Robert J Costantino Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+43.91%
|
-
|
|
Oct 16
2024
|
Diane M Levitan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+50.0%
|
-
|
|
Oct 16
2024
|
Michael Eugene Eldred Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+50.0%
|
-
|
|
Oct 16
2024
|
Joseph William Jasper Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+33.41%
|
-
|
|
Sep 17
2024
|
Garry N Lowenthal Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,000
+41.67%
|
-
|
|
Sep 17
2024
|
John Lai CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+5.29%
|
-
|
|
Sep 17
2024
|
John Fitzgerald Dolan Chief Business Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+7.8%
|
-
|
|
Sep 17
2024
|
Randall A. Meyer Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+3.81%
|
-
|
|
Apr 15
2024
|
John Lai CEO and President |
BUY
Open market or private purchase
|
Direct |
150,000
+10.43%
|
$0
$0.6 P/Share
|
|
Aug 21
2023
|
James Rudolph Martin Director |
BUY
Open market or private purchase
|
Direct |
22,224
+1.32%
|
$44,448
$2.26 P/Share
|
|
Aug 19
2023
|
Joseph William Jasper Chief Financial Officer |
BUY
Payment of exercise price or tax liability
|
Direct |
12,212
+26.0%
|
$12,212
$1.33 P/Share
|
|
Mar 15
2023
|
Robert J Costantino Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,350
+10.82%
|
$10,050
$3.03 P/Share
|
|
Mar 13
2023
|
Joseph William Jasper Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
2,000
+50.0%
|
$6,000
$3.1 P/Share
|
|
Mar 01
2023
|
Joseph William Jasper Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
500
+2.17%
|
$1,000
$2.94 P/Share
|
|
Feb 28
2023
|
Joseph William Jasper Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
501
+2.22%
|
$1,503
$3.12 P/Share
|
|
Feb 27
2023
|
Joseph William Jasper Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,399
+3.17%
|
$2,798
$2.96 P/Share
|
|
Feb 24
2023
|
Joseph William Jasper Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,600
+6.09%
|
$5,200
$2.97 P/Share
|
|
Feb 24
2023
|
John Lai CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
60,600
+5.05%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 540K shares |
|---|---|
| Open market or private purchase | 150K shares |